OasisLMS

1. Utilize appropriate screening methods for individuals with PA
2. Identify the best testing methods to determine an appropriate treatment approach
3. Identify and implement appropriate therapies for individuals with PA

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org.

Gregory Kline, MD
Alberta Health Services
Calgary, Alberta

Anand Vaidya, MD
Brigham and Women's Hospital
Boston, MA

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

• Ananda Vaidya, MD: Advisory Board for Mineralys Therapeutics, HRA Pharma, and Corcept; Consultant, Corcept

The following faculty reported no relevant financial relationships: Gregory Kline, MD

The following subject matter experts who developed the clinical practice guideline used to create this activity reported the following relevant financial relationships: 

• Ricardo Correa, MD: ModernaTX, Consultant; Ascendis Pharma, Speaker; Neurocrine Biosciences, Consultant; Novo Nordisk, Consultant; Boehringer Ingelheim, Consultant
• Paolo Mulatero, MD: Diasorin, Speaker
• William Young, MD: Bayer AG, Consultant, Data Safety Monitoring Board; AstraZeneca, Consultant; Merck Sharp & Dohme, Consultant

The following subject matter experts who developed the clinical practice guideline used to create this activity reported no relevant financial relationships: Gail Adler, MD, PhD; Michael Stowasser, MBBS, FRACP, PhD; Nadia Khan, MD; Michael McGowan; Rhian Touyz, MBBS, MSc, PhD; Tracy Williams, PhD; Jun Yang, MBBS, FRAC, PhD; Maria Christina Zennaro, MD, PhD; M. Hassan Murad, MD, MPH; Juan P. Brito, MBBS

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.